eicosapentaenoic acid ethyl ester and Ischemia

eicosapentaenoic acid ethyl ester has been researched along with Ischemia in 1 studies

Ischemia: A hypoperfusion of the BLOOD through an organ or tissue caused by a PATHOLOGIC CONSTRICTION or obstruction of its BLOOD VESSELS, or an absence of BLOOD CIRCULATION.

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	1 (100.00)	2.80

Authors

Authors	Studies
Peterson, BE	1
Bhatt, DL	1
Steg, PG	1
Miller, M	1
Brinton, EA	1
Jacobson, TA	1
Ketchum, SB	1
Juliano, RA	1
Jiao, L	1
Doyle, RT	1
Granowitz, C	1
Gibson, CM	1
Pinto, D	1
Giugliano, RP	1
Budoff, MJ	1
Tardif, JC	1
Verma, S	1
Ballantyne, CM	1

Clinical Trials (1)

Trial Overview

Trial			Phase	Enrollment	Study Type	Start Date	Status
Evaluation of the Effect of AMR101 on Cardiovascular Health and Mortality in Hypertriglyceridemic Patients With Cardiovascular Disease or at High Risk for Cardiovascular Disease: REDUCE-IT (Reduction of Cardiovascular Events With EPA - Intervention Trial)[NCT01492361]			Phase 3	8,179 participants (Actual)	Interventional	2011-11-30	Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Composite of CV Death or Nonfatal MI (Including Silent MI).

Number of patients with a first occurrence of any component of the composite of CV death or nonfatal MI (including silent MI) during the follow-up period. (NCT01492361)
Timeframe: Total follow-up time of up to approximately 6 years.

Intervention	Participants (Count of Participants)
AMR101	392
Placebo	507

Composite of CV Death, Nonfatal MI (Including Silent MI), Nonfatal Stroke, Coronary Revascularization, or Unstable Angina Determined to be Caused by Myocardial Ischemia by Invasive / Non-invasive Testing and Requiring Emergent Hospitalization.

The primary outcome measure was the number of patients with a first occurrence of any component of the composite of CV death, nonfatal MI (including silent MI), nonfatal stroke, coronary revascularization, or unstable angina determined to be caused by myocardial ischemia by invasive / non-invasive testing and requiring emergent hospitalization during the follow-up period. (NCT01492361)
Timeframe: Total follow-up time of up to approximately 6 years.

Intervention	Participants (Count of Participants)
AMR101	705
Placebo	901

Composite of CV Death, Nonfatal MI (Including Silent MI), or Nonfatal Stroke.

The key secondary outcome measure was the number of patients with a first occurrence of any component of the composite of CV death, nonfatal MI (including silent MI), or nonfatal stroke during the follow-up period. (NCT01492361)
Timeframe: Total follow-up time of up to approximately 6 years.

Intervention	Participants (Count of Participants)
AMR101	459
Placebo	606

CV Death.

Number of patients with an occurrence of CV death during the follow-up period. (NCT01492361)
Timeframe: Total follow-up time of up to approximately 6 years.

Intervention	Participants (Count of Participants)
AMR101	174
Placebo	213

Fatal or Nonfatal MI (Including Silent MI).

Number of patients with a first occurrence of fatal or nonfatal MI (including silent MI) during the follow-up period. (NCT01492361)
Timeframe: Total follow-up time of up to approximately 6 years.

Intervention	Participants (Count of Participants)
AMR101	250
Placebo	355

Fatal or Nonfatal Stroke.

Number of patients with a first occurrence of fatal or nonfatal stroke during the follow-up period. (NCT01492361)
Timeframe: Total follow-up time of up to approximately 6 years.

Intervention	Participants (Count of Participants)
AMR101	98
Placebo	134

Non-elective Coronary Revascularization Represented as the Composite of Emergent or Urgent Classifications.

Number of patients with a first occurrence of non-elective coronary revascularization represented as the composite of emergent or urgent classifications during the follow-up period. (NCT01492361)
Timeframe: Total follow-up time of up to approximately 6 years.

Intervention	Participants (Count of Participants)
AMR101	216
Placebo	321

Total Mortality, Nonfatal MI (Including Silent MI), or Nonfatal Stroke.

Number of patients with a first occurrence of any component of the composite of total mortality, nonfatal MI (including silent MI), or nonfatal stroke during the follow-up period. (NCT01492361)
Timeframe: Total follow-up time of up to approximately 6 years.

Intervention	Participants (Count of Participants)
AMR101	549
Placebo	690

Total Mortality.

Number of patients with an occurrence of death from any cause during the follow-up period. (NCT01492361)
Timeframe: Total follow-up time of up to approximately 6 years.

Intervention	Participants (Count of Participants)
AMR101	274
Placebo	310

Unstable Angina Determined to be Caused by Myocardial Ischemia by Invasive / Non-invasive Testing and Requiring Emergent Hospitalization.

Number of patients with a first occurrence of unstable angina determined to be caused by myocardial ischemia by invasive / non-invasive testing and requiring emergent hospitalization during the follow-up period. (NCT01492361)
Timeframe: Total follow-up time of up to approximately 6 years.

Intervention	Participants (Count of Participants)
AMR101	108
Placebo	157

Trials

1 trial available for eicosapentaenoic acid ethyl ester and Ischemia

Article	Year
Treatment With Icosapent Ethyl to Reduce Ischemic Events in Patients With Prior Percutaneous Coronary Intervention: Insights From REDUCE-IT PCI. Journal of the American Heart Association, 2022, 03-15, Volume: 11, Issue:6 Topics: Double-Blind Method; Eicosapentaenoic Acid; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors;	2022